Modification of MyD88 mRNA splicing and inhibition of IL-1β signaling in cell culture and in mice with a 2′-O-methoxyethyl-modified oligonucleotide

Journal of Immunology

Volumn 176, Issue 6, 2006, Pages 3652-3661

  Vickers, Timothy A ^a   Zhang, Hong ^a   Graham, Mark J ^a   Lemonidis, Kristina M ^a   Zhao, Chenguang ^a   Dean, Nicholas M ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1BETA; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; OLIGONUCLEOTIDE;

ARTICLE; CELL CULTURE; DONOR SITE; EXON; GENE; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RNA SPLICING; SIGNAL TRANSDUCTION;

EID: 33644847417     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.6.3652     Document Type: Article

References (52)

1. Burns, K. C., C. Esslinger, H. Pahl, P. Schneider, J.-L. Bodmer, F. Di Marco, L. French, and J. Tschopp. 1998. MyD88, an adapter protein involved in interleukin-1 signaling. J. Biol. Chem. 273: 12203-12209.
2. Wesche, H., W. J. Henzel, W. Shillinglaw, S. Li, and Z. Cao. 1977. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 7: 837-847.
3. Medzhitov, R., P. Preston-Hurlburt, E. Kopp, A. Stadlen, C. Chen, S. Ghosh, and C. A. Janeway, Jr. 1998. MyD88 is an adaptor protein in the hToll/TL-1 receptor family signaling pathways. Mol. Cell 2: 253-258.
4. Cao, Z., J. Xiong, M. Takeuchi, T. Kurama, and D. V. Goedde. 1996. TRAF6 is a signal transducer for interleukin-1. Nature 383: 443-446.
5. Schnare, M., A. C. Holt, K. Takeda, S. Akira, and R. Medzhitov. 2000. Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr. Biol. 10: 1139-1142.
6. Yamamoto, M., S. Sato, H. Hemmi, H. Sanjo, S. Uematsu, T. Kaisho, K. Hoshino, O. Takeuchi, M. Kobayashi, T. Fujita, et al. 2002. Essential role for TIRAP in activation of the signaling cascade shared by TLR2 and TLR4. Nature 420: 324-329.
7. Kawai, T., O. Adachi, T. Ogawa, K. Takeda, and S. Akira. 1999. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115-122.
8. Bjorkbacka, H., V. V. Kunjathoor, K. J. Moore, S. Koehn, C. M. Ordija, M. A. Lee, T. Means, K. Halmen, A. D. Luster, D. T. Golenbock, and M. W. Freeman. 2004. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med. 10: 416-421.
9. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150.
10. Weighardt, H., S. Kaiser-Moore, R. M. Vabulas, C. J. Kirschning, H. Wagner, and B. Holzmann. 2002. Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J. Immunol. 169: 2823-2827.
11. Janssens, S., K. Burns, J. Tschopp, R. Beyaert. 2002. Regulation of interleukin-1- and lipopolysaccharide-induced NF-κB activation by alternative splicing of MyD88. Curr. Biol. 12: 467-471.
12. Hardiman, G., N. A. Jenkins, N. G. Copeland, D. J. Gilbert, D. K. Garcia, S. L. Naylor, R. A. Kastelein, and J. F. Bazan. 1997. Genetic structure and chromosomal mapping of MyD88. Genomics 45: 332-339.
13. Burns, K., S. Janssens, B. Brissoni, N. Olivos, R. Beyaert, and J. Tschopp. 2003. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 197: 263-268.
14. Maniatis, T., and B. Tasic. 2002. Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature 418: 236-243.
15. Johnson, J. M., J. Castle, P. Garrett-Engele, Z. Kan, P. M. Loerch, C. D. Armour, R. Santos, E. E. Schadt, R. Stoughton, and D. D. Shoemaker. 2003. Genome-wide survey of human alternative pre-mRN A splicing with exon junction microarrays. Science 302: 2141-2144.
16. Yeo, G., S. Hoon, B. Venkatesh, and C. B. Burge. 2004. Variation in sequence and organization of splicing regulatory elements in vertebrate genes. Proc. Natl. Acad. Sci. USA 101: 15700-15705.
17. Sazani, P., and R. Kole. 2003. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J. Clin. Invest. 112: 481-486.
18. S through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotech. 17: 1097-1100.
19. Garcia-Blanco, M. A., A. P. Baraniak, and E. L. Lasda. 2004. Alternative splicing in disease and therapy. Nat. Biotech. 22: 535-546.
20. McKay, R. A., L. J. Miraglia, L. L. Cummins, S. R. Owens, H. Sasmor, and N. M. Dean. 1999. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression. J. Biol. Chem. 274: 1715-1722.
21. Monia, B. P., E. A. Lesnik, C. Gonzalez, W. F. Lima, D. McGee, C. J. Guinosso, A. M. Kawasaki, P. D. Cook, and S. M. Freier. 1993. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268: 14514-14522.
22. Karras, J. G., R. A. McKay, N. M. Dean, and B. P. Monia. 2000. Deletion of individual exons and induction of soluble murine interleukin-5 receptor α chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing. Mol. Pharm. 58: 380-387.
23. Crooke, S. T. 1999. Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta 1489: 30-42.
24. Elbashir, S. M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
25. Caplen, N. J., S. Parrish, F. Imani, A. Fire, and R. A. Morgan. 2001. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA 98: 9742-9747.
26. Baker, B. F., S. S. Lot, T. P. Condon, S. Cheng-Floumoy, E. A. Lesnik, H. M. Sasmor, and C. F. Bennett. 1997. 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272: 11994-12000.
27. Oshiumi, H., K. Funami, T. Akazawa, and T. Seya. 2003. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon- induction. Nat. Immunol. 4: 161-167.
28. Chiang, M.-Y., H. Chan, M. A. Zounes, S. M. Freier, W. F. Lima, and C. F. Bennett. 1991. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266: 18162-18171.
29. Vickers, T. A., J. R. Wyatt, and S. M. Freier. 2000. Effects of RNA secondary structure on cellular antisense activity. Nucleic Acids Res. 28: 1340-1347.
30. Laroia, G., G. Brewer, and R. J. Schneider. 1999. Control of mRNA decay by heat shock-ubiquitin-proteasome pathway. Science 284: 499-502.
31. Winer, J., C. Kwang, S. Jung, I. Shackel, and P. M. Williams. 1999. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal. Biochem. 270: 41-49.
32. Altmann, K.-H., N. M. Dean, D. Fabbro, S. M. Freier, T. Geiger, R. Häner, D. Hüsken, P. Martin, B. P. Monia, M. Müller, et al. 1996. Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia 50: 168-176.
33. Dean, N. M., and R. H. Griffey. 1997. Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 7: 229-233.
34. Sazani, P., S. H. Kang, M. A. Maier, C. Wei, J. Dillman, J. Summerton, M. Manoharan, and R. Kole. 2001. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res. 29: 3965-3974.
35. Springer, T. A. 1990. Adhesion receptors of the immune system. Nature 346: 425-434.
36. Koch, A. E., P. J. Polverini, S. L. Kunkel, L. A. Harlow, L. A. DiPietro, V. M. Elner, and R. M. Strietier. 1992. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258: 1798-1801.
37. Fujishima, S., A. R. Hoffman, T. Vu, K. J. Kim, H. Zheng, D. Daniel, Y. Kim, E. F. Wallace, J. W. Larrick, and T. A. Raffin. 1993. Regulation of neutrophil interleukin 8 gene expression and protein secretion by LPS, TNF-α, and IL-1β. J. Cell. Physiol. 154: 478-485.
38. Medzhitov, R., P. Preston-Hurlburt, and C. A. Janeway, Jr. 1997. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397.
39. An, H., H. Xu, Y. Yu, M. Zhan, R. Qi, X. Yan, S. Liu, W. Wang, Z. Guo, Z. Qin, and X. Cao. 2002. Up-regulation of TLR9 gene expression by LPS in mouse macrophages via activation of NF-κB, ERK and p38 MAPK signal pathways. Immunol. Lett. 81: 165-169.
40. Rhee, S. H., and D. Hwang. 2000. Murine Toll-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF-κB and expression of the inducible cyclooxygenase. J. Biol. Chem. 275: 34035-34040.
41. Henry, S. P., K. Stecker, D. Brooks, D. K. Monteith, B. Conklin, and C. F. Bennett. 2000. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharm. Exp. Ther. 292: 468-479.
42. Modrek, B., and C. Lee. 2001. A genomic view of alternative splicing. Nat. Genet. 30: 13-19.
43. Faustino, N. A., and T. A. Cooper. 2003. Pre-mRNA splicing and human disease. Genes. Dev. 17: 419-437.
44. Crooke, S. T., and C. F. Bennett. 1996. Progress in antisense oligonucleotide therapeutics. Ann. Rev. Pharm. Tox. 36: 107-129.
45. Agami, R. 2002. RNAi and related mechanisms and their potential use for therapy. Curr. Opin. Chem. Biol. 6: 829-834.
46. Mathews, D. H., M. E. Burkard, S. M. Freier, J. R. Wyatt, and D. H. Turner. 1999. Predicting oligonucleotide affinity to nucleic acid targets. RNA 5: 1458-1469.
47. Zhang, H., J. Cook, J. Nickel, R. Yu, K. Stecker, K. Myers, and N. M. Dean. 2000. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotech. 18: 862-867.
48. Zinker, B. A., C. M. Rondinone, J. M. Trevillyan, R. J. Gum, J. E. Clampit, J. F. Waring, N. Xie, D. Wilcox, P. Jacobson, L. Frost, et al. 2002. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. USA 99: 11357-11362.
49. Dean, N. M., and R. McKay. 1994. Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 91: 11762-11766.
50. Sazani, P., F. Gemignani, S. H. Kang, M. A. Maier, M. Manoharan, M. Persmark, D. Bortner, and R. Kole. 2002. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotech. 20: 1228-1233.
51. Lu, Q. L., C. J. Mann, F. Lou, G. Bou-Gharios, G. E. Morris, S. A. Xue, S. Fletcher, T. A. Partridge, and S. D. Wilton. 2003. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med. 9: 1009-1014.
52. Maquat, L. E. 2004. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat. Rev. Mol. Cell Biol. 5: 89-99.